MEsenchymal StEm Cells for Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2013
A double-blind, randomized, cross-over phase I/II study to evaluate the safety and the efficacy of the intravenous administration of autologous Mesenchymal Stem Cells (MSC) to patients with active multiple sclerosis (MS) resistant to currently available therapies.
Epistemonikos ID: f04aedaed4306df669118322e62d39d85a6ce592
First added on: Mar 31, 2022